November 22, 2016 - By Nellie Frank · 0 Comments
The stock of Ziopharm Oncology Incorporated (NASDAQ:ZIOP) registered a decrease of 3.81% in short interest. ZIOP’s total short interest was 37.43 million shares in November as published by FINRA. Its down 3.81% from 38.91M shares, reported previously. With 1.73 million shares average volume, it will take short sellers 22 days to cover their ZIOP’s short positions. The short interest to Ziopharm Oncology Incorporated’s float is 34.94%. The stock closed at $6.41 during the last session. It is down 27.08% since April 20, 2016 and is downtrending. It has underperformed by 31.63% the S&P500.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The company has a market cap of $783.65 million. The Firm is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. It currently has negative earnings. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Out of 3 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Ziopharm Oncology has been the topic of 5 analyst reports since December 4, 2015 according to StockzIntelligence Inc. The firm has “Underperform” rating given on Friday, December 4 by Wells Fargo. Mizuho maintained the shares of ZIOP in a report on Monday, January 25 with “Neutral” rating. Mizuho maintained it with “Neutral” rating and $7 target price in Wednesday, May 11 report. The firm has “Market Perform” rating given on Wednesday, August 10 by Wells Fargo. As per Thursday, June 2, the company rating was initiated by Raymond James.
ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Firm is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
More important recent ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation” on October 14, 2016, also Fool.com published article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Celgene”, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. More interesting news about ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was released by: Fool.com and their article: “Here’s Why Ziopharm Oncology, Inc. Shares Took a Pounding and Lost 30% in June” with publication date: July 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank